Max Herrmann, formerly chief financial officer of the Intercytex Group Plc, has been appointed CFO of Silence Therapeutics Plc, a developer of therapeutics based on RNA interference (RNAi). The appointment takes effect on 4 May 2010.
Before joining Intercytex, Mr Herrmann spent more than 10 years as a sell-side equity analyst, most recently as managing director and head of European pharmaceutical and biotechnology research at the ING Group. Mr Herrmann qualified as a chartered accountant with Arthur Andersen in 1993. He holds a degree in microbiology from the University of Kent in the UK.
Copyright 2010 Evernow Publishing Ltd